Cardiac protection by pharmacological modulation of inflammation

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1913-1924

  Latini, R ^a   Masson, S ^a   Bertini, R ^a   Maggioni, A P ^a   Ghezzi, P ^a   Calvillo, L ^a  

^a Ist Ricerche Farmacol Mario Negri ^*  (Italy)

Author keywords

Adenosine; Antibiotics; Atherosclerosis; Chemokines; Cytokines; Inflammation; Myocardial ischaemia; Neutrophils; PMN; Reperfusion; Strains

Indexed keywords

1,10 PHENANTHROLINE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; ADENOSINE RECEPTOR; ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPYRIDAMOLE; DOXYCYCLINE; DRAFLAZINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GATIFLOXACIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NITRIC OXIDE; PENTRAXIN; PLACEBO; PRAVASTATIN; ROVELIZUMAB; ROXITHROMYCIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOVASCULAR SYSTEM; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; ENVIRONMENT; HEART DISEASE; HEART INJURY; HEART PROTECTION; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; INJURY; ISCHEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MODULATION; NONHUMAN; PHARMACOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT; REPERFUSION; REVIEW; VASCULAR DISEASE;

ADENOSINE; ANIMALS; BACTERIAL INFECTIONS; CARDIOVASCULAR AGENTS; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; ENZYME INHIBITORS; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MATRIX METALLOPROTEINASES; NEUTROPHILS; REACTIVE OXYGEN SPECIES;

EID: 0035164964     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1913     Document Type: Review

References (115)

1. The speed of healing of myocardial infarction. A study of the pathologic anatomy in seventy-two cases
2. The 'wavefront phenomenon' of myocardial ischemic cell death
3. Ten years of benefit from a one-hour intervention
4. Progression of myocardial necrosis during reperfusion of ischemic myocardium
5. Does reperfusion injury exist in humans?
6. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease
7. Role of neutrophils in myocardial ischemia and reperfusion
8. In vivo models of myocardial ischemia and reperfusion injury. Application to drug discovery and evaluation
9. The EMIP project
10. Deleterious effects of methylprednisolone in patients with myocardial infarction
11. Atherosclerosis - An inflammatory disease
12. Steroid administration after myocardial infarction promotes early infarct expansion. A study in the rat
13. Steroid therapy during acute myocardial infarction: A cause of delayed healing and of ventricular aneurysm
14. Role of neutrophils in myocardial ischemia-reperfusion injury
15. Therapeutic potential of complement inhibitors in myocardial ischaemia
16. Neutrophil adherence to isolated adult canine myocytes
17. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction
18. TNF-α and heart failure. The difference between proof of principle and hypothesis testing
19. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
20. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
21. Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines
22. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo
23. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction
24. Reduction of ischemia-reperfusion injury in the rat in vivo by DF-1681A, an inhibitor of interleukin-8
25. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: A study of myocardial enzyme release
26. Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts
27. Reperfusion injury
28. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase
29. 'Reperfusion injury' by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, myocardial blood flow
30. Oxygen radical scavenger agents as adjuvant therapy with tissue plasminogen activator in a canine model of thrombolysis
31. Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury
32. Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs
33. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction
34. Can superoxide dismutase alter myocardial infarct size?
35. Superoxide dismutase 10 years later: A drug in search of a use
36. 2+ levels
37. In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation
38. Control of the acute phase response. Serum C-reactive protein after acute myocardial infarction
39. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
40. Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina
41. Direct proinflammatory effect of C-reactive protein on human endothelial cells
42. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction
43. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia
44. Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling
45. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
46. Inflammation, aspirin, and risks of cardiovascular disease in apparently health men
47. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently health women
48. Multimer formation and ligand recognition by the long pentraxin PTX3: Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component
49. Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites
50. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction
51. Chronic infections and coronary heart disease: Is there a link?
52. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study
53. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study
54. Description and status of the azithromycin and coronary events study (ACES)
55. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial
56. Current perspectives on statins
57. New evidence for beneficial effects of statins unrelated to lipid lowering
58. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells
59. Inhibition of monocyte chemotactic protein-1 synthesis by statins
60. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome (PPARα) in primary endothelial cells
61. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
62. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies
63. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
64. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
65. Reduction of serum cholesterol levels alters lesional composition of atheroslecrotic plaques: Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
66. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
67. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
68. Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response
69. Simavastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
70. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
71. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
72. Effect of pravastatin on outcomes after cardiac transplantation
73. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients
74. Statins as a newly recognized type of immunosuppressor
75. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
76. For the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein
77. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
78. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
79. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor I patients undergoing coronary artery bpass graft surgery with cardiopulmonary bypass
80. Complement activation in patients with congestive heart failure. Effect of high-dose intravenous immunoglobulin treatment
81. Adenosine therapy: New approach to chronic heart failure
82. Protective effects of adenosine in myocardial ischemia
83. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-α
84. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils
85. ATP channels and ischemic preconditioning in dogs
86. 2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium
87. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence
88. 3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury
89. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and no-reflow phenomenon
90. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: Effects on infarct size, ventricular function, and regional myocardial blood flow
91. Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bcl-2 and Bax proteins
92. The late phase of preconditioning
93. Adenosine, adenosine receptors and myocardial protection: An updated overview
94. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries. Role of adenosine
95. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction
96. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction Study of Adenosine (AMISTAD)
97. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction
98. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes, and injury
99. Timely administration of AICA riboside reduces reperfusion injury in rabbits
100. The acute effects of AICAR on purine nucleotide metabolism and postischemic cardiac function
101. Failure of AICA riboside to limit infarct size during acute myocardial infarction in rabbits
102. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials
103. The cardiac effects of adenosine
104. Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine
105. Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that binds
106. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation
107. Reactive oxygen species produced by macrophage-derived from cells regulate the activity of vascular matrix metalloproteinases in vitro
108. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury
109. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts
110. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite
111. Decreased expression of tissue inhibitor of metalloproteinase-1 in stunned myocardium
112. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart
113. Matrix-dependent mechanism of neutrophil mediated release and activation of matrix metalloproteinase-9 in myocardial ischemia/reperfusion
114. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4 and GRO-alpha and leaves RANTES and MCP-2 intact
115. For want of a few good shams